CUSIP: 85858C107
Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
12,881,851
-
Share change
-
+270,980
-
Total reported value
-
$142,990,719
-
Put/Call ratio
-
533%
-
Price per share
-
$11.10
-
Number of holders
-
76
-
Value change
-
+$3,118,281
-
Number of buys
-
32
-
Number of sells
-
25
Quarterly Holders Quick Answers
What is CUSIP 85858C107?
CUSIP 85858C107 identifies STML - STEMLINE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2017
-
Previous quarter:
Q2 2017
Recent filing periods for CUSIP 85858C107:
Institutional Holders of STEMLINE THERAPEUTICS INC - COM (STML) as of Q3 2017
As of 30 Sep 2017,
STEMLINE THERAPEUTICS INC - COM (STML) was held by
76 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,881,851 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, EVENTIDE ASSET MANAGEMENT, LLC, VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., BAKER BROS. ADVISORS LP, AXA, Lyon Street Capital, LLC, and STATE STREET CORP.
This page lists
76
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.